Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)
NCT ID: NCT00074906
Last Updated: 2012-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1200 participants
INTERVENTIONAL
2003-11-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atropine for Preventing Ventilator-Associated Pneumonia
NCT02704923
Can a Vocal Stimulus Provoke Spontaneous Breathing in an Ischemic Stroke Patient Dependent on Mechanical Ventilation?
NCT02114996
Ventilator Inspiratory Trigger Sensitivity Adjustment Versus Threshold Device Training on Pulmonary Functions in Acute Stroke Patients
NCT07003867
Pulmonary Infections and Barotrauma Associated With MV IN PICU
NCT05792501
Fiberoptic Bronchoscopy in Severe Ventilator-associated Pneumonia
NCT07149909
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venticute
Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Severe pre-existing lung disease
* Cancer metastatic to the lung or any end stage malignancy
* History of lung, liver, pancreas, small bowel, or bone marrow/stem cell transplantation
* Patient is morbidly obese
* Patient has a diagnosis of acute necrotizing pancreatitis
Additional criteria may apply and examination by an investigator is required to determine eligibility.
12 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roger G. Spragg, MD
Role: PRINCIPAL_INVESTIGATOR
University of California and La Jolla Veterans Affairs Medical Center, San Diego, CA, USA
Werner Seeger, MD
Role: PRINCIPAL_INVESTIGATOR
Justus-Liebig-Universität, Gießen, Germany
Andreas Günther, MD
Role: PRINCIPAL_INVESTIGATOR
University of Giessen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana Pharma/Nycomed
Adelaide SA, , Australia
Altana Pharma/Nycomed
Bedford Park, Adelaide S, , Australia
Altana Pharma/Nycomed
Clayton, VIC, , Australia
Altana Pharma/Nycomed
Fremantle, WA, , Australia
Altana Pharma/Nycomed
Heidelberg, Victoria, , Australia
Altana Pharma/Nycomed
Kingswood, Sydney, NS, , Australia
Altana Pharma/Nycomed
Melbourne VIC, , Australia
Altana Pharma/Nycomed
Perth, Western Australi, , Australia
Altana Pharma/Nycomed
Southport Gold Coast QL, , Australia
Altana Pharma/Nycomed
Victoria, , Australia
Altana Pharma/Nycomed
Victoria, , Australia
Altana Pharma/Nycomed
Woolloongabba, Queens, , Australia
Altana Pharma/Nycomed
Linz, , Austria
Altana Pharma/Nycomed
Vienna, , Austria
Altana Pharma/Nycomed
Brussels, , Belgium
Altana Pharma/Nycomed
Brussels, , Belgium
Altana Pharma/Nycomed
Edegern, , Belgium
Altana Pharma/Nycomed
Ghent, , Belgium
Altana Pharma/Nycomed
Copenhagen NV, , Denmark
Altana Pharma/Nycomed
Hvidovre, , Denmark
Altana Pharma/Nycomed
Kolding, , Denmark
Altana Pharma/Nycomed
Tallinn, , Estonia
Altana Pharma/Nycomed
Tartu, , Estonia
Altana Pharma/Nycomed
Jyväskylä, , Finland
Altana Pharma/Nycomed
Kuopio, , Finland
Altana Pharma/Nycomed
Lappeenranta, , Finland
Altana Pharma/Nycomed
Oulu, , Finland
Altana Pharma/Nycomed
Tampere, , Finland
Altana Pharma/Nycomed
Turku, , Finland
Altana Pharma/Nycomed
Berlin, , Germany
Altana Pharma/Nycomed
Bonn, , Germany
Altana Pharma/Nycomed
Dresden, , Germany
Altana Pharma/Nycomed
Giessen, , Germany
Altana Pharma/Nycomed
Greifswald, , Germany
Altana Pharma/Nycomed
Hanover, , Germany
Altana Pharma/Nycomed
Hofheim, , Germany
Altana Pharma/Nycomed
Konstanz, , Germany
Altana Pharma/Nycomed
Lübeck, , Germany
Altana Pharma/Nycomed
München, , Germany
Altana Pharma/Nycomed
Regensburg, , Germany
Altana Pharma/Nycomed
Tübingen, , Germany
Altana Pharma/Nycomed
Athens, , Greece
Altana Pharma/Nycomed
Dragana, Alexandroupoli, , Greece
Altana Pharma/Nycomed
Thessaloniki, , Greece
Altana Pharma/Nycomed
Voutes, Crete, , Greece
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Kistarcsa, , Hungary
Altana Pharma/Nycomed
Szeged, , Hungary
Altana Pharma/Nycomed
Székesfehérvár, , Hungary
Altana Pharma/Nycomed
Vác, , Hungary
Altana Pharma/Nycomed
Afula, , Israel
Altana Pharma/Nycomed
Tel Litwinsky, , Israel
Altana Pharma/Nycomed
Ẕerifin, , Israel
Altana Pharma/Nycomed
Breda, , Netherlands
Altana Pharma/Nycomed
Heerlen, , Netherlands
Altana Pharma/Nycomed
Rotterdam, , Netherlands
Altana Pharma/Nycomed
Tilburg, , Netherlands
Altana Pharma/Nycomed
Christchurch, , New Zealand
Altana Pharma/Nycomed
Hastings, , New Zealand
Altana Pharma/Nycomed
Wellington, , New Zealand
Altana Pharma/Nycomed
Moscow, , Russia
Altana Pharma/Nycomed
Moscow, , Russia
Altana Pharma/Nycomed
Moscow, , Russia
Altana Pharma/Nycomed
Moscow, , Russia
Altana Pharma/Nycomed
Moscow, , Russia
Altana Pharma/Nycomed
Johannesburg, , South Africa
Altana Pharma/Nycomed
Queenswood, , South Africa
Altana Pharma/Nycomed
Badajoz, , Spain
Altana Pharma/Nycomed
Barcelona, , Spain
Altana Pharma/Nycomed
Barcelona, , Spain
Altana Pharma/Nycomed
Getafe (Madrid), , Spain
Altana Pharma/Nycomed
Granada, , Spain
Altana Pharma/Nycomed
Madrid, , Spain
Altana Pharma/Nycomed
Palma de Mallorca, , Spain
Altana Pharma/Nycomed
Seville, , Spain
Altana Pharma/Nycomed
Seville, , Spain
Altana Pharma/Nycomed
Bern, , Switzerland
Altana Pharma/Nycomed
Lugano, , Switzerland
Altana Pharma/Nycomed
Winterthur, , Switzerland
Altana Pharma/Nycomed
Zurich, , Switzerland
Altana Pharma/Nycomed
Budapest, , United Kingdom
Altana Pharma/Nycomed
Cardiff, , United Kingdom
Altana Pharma/Nycomed
Cottingham, , United Kingdom
Altana Pharma/Nycomed
Kings Lynn, Norfolk, , United Kingdom
Altana Pharma/Nycomed
Leeds, , United Kingdom
Altana Pharma/Nycomed
Leeds, , United Kingdom
Altana Pharma/Nycomed
Nottingham, , United Kingdom
Altana Pharma/Nycomed
Reading, , United Kingdom
Altana Pharma/Nycomed
West Lothian, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spragg RG, Taut FJ, Lewis JF, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, Gunther A. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1055-61. doi: 10.1164/rccm.201009-1424OC. Epub 2010 Dec 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY2001/M1-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.